INS and type 2 diabetes mellitus: Liraglutide, an insulin secretagogue, and other drugs available for treating T2DM are strong candidates to repurpose for AD and hit multiple targets, representing an example of polypharmacology over polypharmacy in the repurposing of drugs for their side effects in AD77.